BEAC预处理自体造血干细胞移植治疗淋巴瘤的疗效观察
0引言 恶性淋巴瘤(ML)是淋巴系统常见的恶性肿瘤,对放化疗敏感,常规治疗可使60%的霍奇金病(Hodgkin’s disease,HD)和30%~50%的非霍奇金淋巴瘤(non-Hodgkin’s disease,NHL)患者得到治愈或长期无病生存,但对恶性度高、耐药及难治的ML疗效差。有研究显示,初治侵袭性淋巴瘤,...
Saved in:
Published in | 肿瘤防治研究 Vol. 38; no. 11; pp. 1324 - 1325 |
---|---|
Main Author | |
Format | Journal Article |
Language | Chinese |
Published |
2011
|
Subjects | |
Online Access | Get full text |
ISSN | 1000-8578 |
Cover
Summary: | 0引言
恶性淋巴瘤(ML)是淋巴系统常见的恶性肿瘤,对放化疗敏感,常规治疗可使60%的霍奇金病(Hodgkin’s disease,HD)和30%~50%的非霍奇金淋巴瘤(non-Hodgkin’s disease,NHL)患者得到治愈或长期无病生存,但对恶性度高、耐药及难治的ML疗效差。有研究显示,初治侵袭性淋巴瘤, |
---|---|
Bibliography: | 42-1241/R |
ISSN: | 1000-8578 |